Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Cooperative Study Group.
Westin, J, Rödjer, S, Turesson, I et al.·British journal of haematology·1995
This study tested whether a drug called interferon alfa-2b could help multiple myeloma patients (a type of blood cancer) stay in remission longer after their initial treatment. Patients who received interferon stayed in remission for about 14 months compared to 6 months for those who didn't, but both groups lived about the same length of time overall.